polatuzumab vedotin + rituximab

Polatuzumab vedotin + rituximab is a combination regimen used primarily for treating diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), especially in cases where disease is relapsed or refractory. **Polatuzumab vedotin** is an antibody-drug conjugate (ADC) targeting CD79b, a B-cell antigen, and delivers the cytotoxic agent monomethyl auristatin E (MMAE) into malignant B cells; MMAE disrupts microtubules, leading to cell cycle arrest and apoptosis. **Rituximab** is a monoclonal antibody targeting the CD20 receptor on B lymphocytes, inducing cell death via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The combination has demonstrated additive or synergistic antitumor effects, with polatuzumab vedotin shown to increase CD20 expression and thereby augment rituximab-mediated CDC and ADCC. This regimen is typically part of combination therapies (e.g., with bendamustine or other chemotherapeutics); its principal development and clinical use are for DLBCL not otherwise specified and HGBL in both previously untreated and relapsed/refractory settings[2][4][5].

Other names

pola + rituximabpolatuzumab vedotin + ritpola-Rpolatuzumab rituximab